Quantification of different iron forms in the aceruloplasminemia brain to explore iron-related neurodegeneration
================================================================================================================

* Lena H.P. Vroegindeweij
* Lucia Bossoni
* Agnita J.W. Boon
* J.H. Paul Wilson
* Marjolein Bulk
* Martina Huber
* Jacqueline Labra-Muñoz
* Andrew Webb
* Louise van der Weerd
* Janneke G. Langendonk

## Abstract

**Introduction** Aceruloplasminemia is an ultra-rare neurodegenerative disorder associated with massive brain iron accumulation. It is unknown which molecular forms of iron accumulate in the brain of patients with aceruloplasminemia. As the disease is associated with at least a fivefold increase in brain iron concentration compared to the healthy brain, it offers a unique model to study the role of iron in neurodegeneration and the molecular basis of iron-sensitive MRI contrast.

**Methods** The iron-sensitive MRI metrics inhomogeneous transverse relaxation rate (R2*) and magnetic susceptibility obtained at 7T were combined with Electron Paramagnetic Resonance (EPR) and Superconducting Quantum Interference Device (SQUID) magnetometry to specify and quantify the different iron forms per gram wet weight in a post-mortem aceruloplasminemia brain, focused on the basal ganglia, thalamus, red nucleus, dentate nucleus, superior- and middle temporal gyrus and white matter. MRI, EPR and SQUID results that had been previously obtained from the temporal cortex of healthy controls were included for comparison.

**Results** The brain iron pool in aceruloplasminemia consisted of EPR-detectable Fe3+ ions, magnetic Fe3+ embedded in the core of ferritin and hemosiderin (ferrihydrite-iron), and magnetic Fe3+ embedded in oxidized magnetite/maghemite minerals (maghemite-iron). Of all the studied iron pools, above 90% was made of ferrihydrite-iron, of which concentrations up to 1065 µg/g were detected in the red nucleus. Although deep gray matter structures in the aceruloplasminemia brain were three times richer in ferrihydrite-iron than the temporal cortex, ferrihydrite-iron was already six times more abundant in the temporal cortex of the patient with aceruloplasminemia compared to the healthy situation (162 µg/g vs. 27 µg/g). The concentration of Fe3+ ions and maghemite-iron was 1.7 times higher in the temporal cortex in aceruloplasminemia than in the control subjects. Of the two quantitative MRI metrics, R2* was the most illustrative of the pattern of iron accumulation and returned relaxation rates up to 0.49 ms-1, which were primarily driven by the abundance of ferrihydrite-iron. Maghemite-iron did not follow the spatial distribution of ferrihydrite-iron and did not significantly contribute to MRI contrast in most of the studied regions.

**Conclusions** Even in extremely iron-loaded cases, iron-related neurodegeneration remains primarily associated with an increase in ferrihydrite-iron, with ferrihydrite-iron being the major determinant of iron-sensitive MRI contrast.

Keywords
*   Aceruloplasminemia
*   iron
*   post-mortem MRI
*   ferritin
*   magnetometry

## Introduction

Aceruloplasminemia (OMIM #604290) is a severe adult-onset form of Neurodegeneration with Brain Iron Accumulation (NBIA), caused by homozygous or compound heterozygous mutations in the ceruloplasmin (*CP*) gene. Iron accumulation in aceruloplasminemia has been directly linked to its genetic background, as ceruloplasmin-mediated oxidation of ferrous iron (Fe2+) to ferric iron (Fe3+) is a prerequisite for transport of iron across cell membranes and for binding to transferrin (1). As a result of ceruloplasmin dysfunction in the brain leading to insufficient cellular iron efflux, iron accumulates within perivascular astrocytes, with total iron concentrations reaching over 600 µg/g in the basal ganglia (2), which is at least five times the normal concentration (3, 4). However, the exact role of different iron forms in the pathophysiology and clinical phenotype of aceruloplasminemia is still not clear. Molecular specification of the massive iron pool in aceruloplasminemia brain can aid our understanding of iron related neurodegeneration, and perhaps improve therapeutic considerations, which are currently based on iron chelation.

Among the molecular forms in which iron can be found in the brain, three are particularly relevant. In the healthy human brain, iron is predominantly stored within the core of ferritin and hemosiderin, in the form of Fe3+- containing ferrihydrite nanocrystals (Fe2O3•0.5H2O) (5). These iron stores are generally regarded as non-damaging and are required for normal brain function. In contrast, Fe2+ ions taking part in the labile iron pool have been associated with iron-related neuronal damage through generation of free radicals via the Fenton reaction (1, 5, 6). The iron-oxide magnetite (Fe3O4) is a carrier of Fe2+ and might thus play a prominent role in iron-related neurodegeneration (5, 7). Histochemical studies in aceruloplasminemia have indicated an abundance of ferritin-bound iron (8, 9), and smaller amounts of Fe2+ carriers (8, 10). However, no quantitative studies have been performed to further determine the molecular forms of iron and their distribution throughout the aceruloplasminemia brain.

Iron-sensitive MRI techniques have been commonly applied as an indirect measure of brain iron content in neurodegenerative disorders, using the effect that (para)magnetic iron has on the proton nuclear relaxation rate (R2*) and on the magnetic susceptibility of the tissue, which can be measured by Quantitative Susceptibility Mapping (QSM) (11, 12). Although R2* mapping is recognized as a robust method to infer iron accumulation in brain tissue, it is affected by several confounders such as cell water content, the macromolecular pool and myelin. In particular, myelin and iron have the same effect on R2* values (13). QSM, on the other hand, has the potential to differentiate between myelin and iron, based on their opposite effects on tissue susceptibility (14), and seems less affected by the cellular localization of iron (15). Both iron-sensitive MRI techniques have been used for the quantitative assessment of iron in aceruloplasminemia brain tissue (16, 17), but only provided total iron concentrations and not their specification (18).

The primary aim of this study was to directly quantify different molecular iron forms in the aceruloplasminemia brain. For this purpose, we performed Electron Paramagnetic Resonance (EPR) and Superconducting Quantum Interference Device (SQUID) magnetometry on ten brain regions derived from a post-mortem aceruloplasminemia brain. It should be stressed that, due to the rarity of the disease, aceruloplasminemia brain material is extremely scarce. We present a quantitative overview of Fe3+ ions detected by EPR, and magnetic Fe3+ embedded in ferritin cores or hemosiderin (ferrihydrite-iron) and oxidized magnetite/maghemite minerals (maghemite-iron), as detected by magnetometry. R2* and QSM maps from the same regions are shown with the additional aim to illustrate the extent to which different iron forms affect iron-sensitive MRI metrics. Since MRI is the major imaging modality capable of studying brain iron accumulation *in vivo*, further specification of the molecular basis of iron-sensitive MRI contrast is key to gain more in-depth pathophysiological insights into different clinical stages of iron-related neurodegeneration.

## Methods

### Brain tissue selection

Formalin-fixed brain slices of one end-stage aceruloplasminemia patient (male, age range: 50-55) (19-22) were obtained from the Department of Pathology, Erasmus MC, University Medical Center Rotterdam, The Netherlands. This study has received IRB approval by the Erasmus MC Medical Ethical Committee (MEC-2011-525).

The brain slices had been stored in formalin for 5 years. Tissue blocks of approximately 30 × 30 × 10 mm3 were dissected, including the basal ganglia, thalamus, red nucleus, dentate nucleus, superior- and middle temporal gyrus and white matter. Ceramic tools were used to prevent metal contamination of the samples.

### MRI data acquisition and data analysis

Before MRI, the dissected tissue blocks were rehydrated in phosphate buffered saline (PBS) for 24 hours and immersed in a proton-free solution (Fomblin LC08, Solvay). ICP-MS detected iron traces up to 3.5 µg/ml in the formalin solution, likely due to leakage of iron from the tissue over time. MRI scans were performed at room temperature on a 7 T preclinical scanner (Bruker Biospin, Ettlingen, Germany) using a 38-mm quadrature RF coil. For each tissue sample a three-dimensional multi-gradient-echo sequence (MGE) was used with eight equally spaced echoes. First echo-time was 1.96 ms, echo spacing was 2.21 ms, repetition time was 130.4 ms, flip angle was 25°, 150 µm3 isotropic spatial resolution. 20 averages were acquired. The total acquisition time was 3h 54minutes.

R2* (1/T2*) maps were obtained by fitting the signal decay of the magnitude images to a mono-exponential decay function. Susceptibility values (χ) were obtained from the eight-echoes phase images of the MGE data, with the STI-Suite software (version 2.2)(23). Phase unwrapping of the measured phase images and removal of the background field was done with the iHARPERELLA algorithm (24), while magnetic susceptibility estimation and streaking artifact correction was performed with the ‘iLSQR’ algorithm (25). Raw susceptibility values are reported, as no reference region was available in these small tissue samples. Regions of interest (ROIs) were manually drawn within each deep gray matter region, middle temporal gyrus and temporal white matter. For each ROI, mean R2* and magnetic susceptibility values were reported.

Additional MR images that had been previously acquired using tissue blocks from the temporal cortex and the striatum of two control subjects are used as references to illustrate the effect of iron accumulation in the aceruloplasminimia brain on MRI maps. These control tissue blocks had been scanned with an acquisition protocol as described above, with the exception of the echo timing, which was increased as the iron concentration was much lower in these control cases: The first echo time was 12.5 ms long, and the inter-echo time was 10.7 ms (26).

### EPR experiments and spectra fitting

After MRI, subsections of approximately 40 mg were taken from each gray and white matter structure in the tissue blocks (Figure 1). The resulting subsections were prepared for EPR as previously described (27). The 9 GHz continuous wave EPR measurements were performed at 6 K using an ELEXSYS E680 spectrometer (Bruker, Rheinstetten, Germany) equipped with a rectangular cavity. The microwave frequency was 9.4859 GHz, modulation frequency 90 kHz, power attenuation 20 dB, receiver gain 60 dB and modulation amplitude 6 Gpp. Power attenuation was chosen after a progressive power saturation experiment (Supplementary material, Figure S1). The accumulation time was approximately five minutes per spectrum.

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/10/20/2020.10.15.20206102/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2020/10/20/2020.10.15.20206102/F1)

Figure 1. Pipeline of the experimental protocol.
In this example, the basal ganglia (caudate nucleus – CN, putamen – PU, globus pallidus – GP), were dissected from the appropriate brain slab and prepared for MRI. Following MRI, small subsections were taken from each basal ganglion structure and prepared for EPR. Regions of interest (ROIs) on the MRI were matched with the EPR sampling locations. For SQUID, subsections of tissue were taken adjacent to the sampling locations for EPR. Scale bar in the bottom figures, 1 cm.

Figure 2 shows a baseline-corrected EPR spectrum of the putamen tissue block, consisting of several bands. In this work, we focused on the low field g’=4.3 band, which originates from high-spin Fe3+ complexed in a site of low symmetry (27). A close look at the temperature dependence of the band suggests the presence of a weak antiferromagnetic coupling (Supplementary material, Figure S2).

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/10/20/2020.10.15.20206102/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2020/10/20/2020.10.15.20206102/F2)

Figure 2. Determination of Fe3+ ions by Electron Paramagnetic Resonance (EPR) at 6 K.
First derivative, baseline corrected EPR spectrum of the putamen. The spectrum consists of several bands: a g’∼7 poorly defined signal, a weak band at g’=6, an intense band at g’=4.3, a largely asymmetric band around g’=2.04, and a narrow band at g’=2.008.

The g’=4.3 bands detected in each sample were fit to the spin Hamiltonian which describes high-spin Fe3+ (27). EPR spectra simulations and fitting were done with EasySpin version 5.2.28 (28). Fitting parameters and examples of the fitted spectra are shown in the Supplementary material (Table S1 and Figure S3). The Fe3+ concentration of each sample was calculated by taking the second integral of the fitted spectrum and comparing it to the second integral of a reference solution Fe-EDTA of known Fe3+ concentration (35.7 µM).

### Magnetometry experiments

Following EPR experiments, subsections were taken from the caudate nucleus, putamen, substantia nigra, thalamus, red nucleus, dentate nucleus, temporal cortex and white matter, mostly adjacent to the sampling locations for EPR. The total volume of specimens for each brain region was approximately 10 x 10 x 10 mm3. The globus pallidus was not included because of its smaller volume. Tissue samples were removed from formalin, frozen in liquid nitrogen, and freeze-dried. The brain material was subsequently pelleted and placed in the sample holder of a Superconducting Quantum Interference Device (SQUID) magnetometer.

Isothermal Remanent Magnetization (IRM) curves were acquired with a Quantum Design MPMS-XL SQUID magnetometer with the Reciprocating Sample Option (RSO) probe, as reported previously (18, 27), to explore whether the samples retained magnetization outside of an external magnetic field following stepwise exposure to higher magnetic field strengths at a constant temperature (29, 30). Two IRM curves were acquired: one at 5 K, which can report on ferrihydrite, the mineral found in the core of ferritin proteins and hemosiderin aggregates; and a second at 100 K, which saturated around 250 mT, indicative of magnetite or its oxidation product, maghemite. An example of the IRM curves for one of the samples is shown in Figure 3. The IRM values were obtained after dividing the raw magnetic moment by the wet weight (ww) of the sample. Saturation IRM values (SIRM) were extracted by fitting the IRM curves to an offset-corrected Langevin model, as in our previous work (18).

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/10/20/2020.10.15.20206102/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2020/10/20/2020.10.15.20206102/F3)

Figure 3. Determination of ferrihydrite and maghemite by Isothermal Remanent Magnetization (IRM).
IRM curves of the dentate nucleus at 5K (left) and 100 K (right). The IRM curve at 100 K saturates around 0.25 mT, which is a strong indication for the presence of magnetite or maghemite.

Ferrihydrite and maghemite concentrations were estimated by dividing the SIRM values by the saturation magnetization (Ms) of the specific mineral: Ms= 0.62 Am2/kg for ferrihydrite (31), and 74 Am2/kg for maghemite (32). Maghemite was chosen instead of magnetite, due to the high chance of sample oxidation during tissue processing. Subsequently, the ferrihydrite-iron and maghemite-iron concentrations were calculated by multiplying the mineral concentration by the iron mass-ratio for the given mineral. Concentrations of Fe3+, ferrihydrite-iron and maghemite-iron that had been previously obtained under identical conditions from the temporal cortex of healthy controls were provided for comparison (18).

Raw data post-processing of MRI, EPR and SQUID data was performed with an in-house written code in MatlabR2016a.

## Results

Table 1 provides an overview of all data collected from the aceruloplasminemia brain. The highest R2* values were found in the red nucleus, lateral division of the thalamus and substantia nigra. On average, R2* values within deep gray matter structures in aceruloplasminemia were over two times higher than those obtained from the temporal cortex. The deep gray matter structures in aceruloplasminemia had at least a three-fold increase in relaxation rates with respect to the close-by white matter, while in the temporal cortex the relative gray matter/white matter relaxation rates was reversed. Higher relaxation rates were observed in the white matter, which indicates a large fraction of iron being embedded in myelin. In the control subjects, both the white matter of the internal capsule and of the temporal lobe showed higher relaxation rates compared to the close-by gray matter (Figure 4), but in all regions the relaxation rates were substantially lower than for the aceruloplasminemia case. Susceptibility values in aceruloplasminemia were only partially in accordance with the pattern of iron accumulation as suggested by the R2* maps and were more heterogeneous (Figure 4). Notable exceptions were the dentate nucleus, parts of the putamen and the temporal white matter, where a striking paramagnetic component was observed compared to close-by structures.

View this table:
[Table 1.](http://medrxiv.org/content/early/2020/10/20/2020.10.15.20206102/T1)

Table 1. Overview of MRI, EPR and SQUID results obtained from the aceruloplasminemia brain.

![Figure 4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/10/20/2020.10.15.20206102/F4.medium.gif)

[Figure 4.](http://medrxiv.org/content/early/2020/10/20/2020.10.15.20206102/F4)

Figure 4. Comparison of quantitative MRI results.
The obtained R2* maps are shown with the regions of interest (ROIs) outlined and the corresponding QSM maps for the temporal cortex (1) and white matter (2) (A, B), putamen (3), caudate nucleus (4) and globus pallidus (5) (D, E), dentate nucleus (6) (G, H), thalamus (7 – lateral division, 8 – medial division), substantia nigra (9) and red nucleus (10) (I, J) in aceruloplasminemia. Note that for the red nucleus, in which the highest R2* values were found, the susceptibility signal was mostly marked out (J). R2* maps of the temporal cortex (1) and white matter (2) (C), putamen (3) and caudate nucleus (4)(F) of a control subject are provided for comparison. Scalebar, 1 cm.

Ferrihydrite-iron was the most abundant form of iron in all investigated brain regions in aceruloplasminemia, and represented 91-98% of all iron (Table 1). Mean concentrations of ferrihydrite-iron in the deep gray matter reached over 500 µg/g wet weight, and were three times higher compared to the temporal cortex, which already exceeded the healthy situation by six times. The amount of Fe3+ ions and maghemite-iron was 1.7 times increased in the temporal cortex of the patient with aceruloplasminemia compared to the control subjects. Although the ferrihydrite/maghemite-iron ratio was highly variable among structures, ferrihydrite-iron was at least three orders of magnitude more abundant than maghemite-iron, on average.

The distribution of Fe3+ ions and iron mineralization products in the aceruloplasminemia brain is visualized in Figure 5. The globus pallidus and medial division of the thalamus, together with regions in the brain stem and cerebellum, showed the highest EPR-detectable Fe3+ concentration. The distribution of maghemite-iron appeared partially in accordance with this pattern, with the medial division of the thalamus, red nucleus, substantia nigra and dentate nucleus being the richest in this mineral form of iron. Maghemite levels in the lateral division of the thalamus and the putamen were below the detection limit of the technique.

![Figure 5.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2020/10/20/2020.10.15.20206102/F5.medium.gif)

[Figure 5.](http://medrxiv.org/content/early/2020/10/20/2020.10.15.20206102/F5)

Figure 5. Distribution of different iron forms in aceruloplasminemia brain tissue.
Abbreviations: DN – dentate nucleus, SN – substantia nigra, RN – red nucleus, THM – medial division of the thalamus, THL – lateral division of the thalamus, CN – caudate nucleus, GP – globus pallidus, PU – putamen, WM – white matter, GM – gray matter.

## Discussion

In this work, the iron-sensitive metrics R2* and QSM obtained from 7 T MRI were combined with Electron Paramagnetic Resonance (EPR) and SQUID magnetometry to specify and quantify the different iron forms in the aceruloplasminemia brain. We detected and quantified ferrihydrite-iron – which is a measure of iron stores in the brain, maghemite-iron – an iron form that is recently attracting the attention of MR-physicists and biologists due to its potential neurotoxicity and the influence that it may have on MRI signal dephasing, and an EPR-sensitive pool of Fe3+ ions.

The comparison between R2* and QSM maps indicated that a (para)magnetic source is driving the increase in relaxation rate in both gray and white matter structures in aceruloplasminemia. We ascribe this source to iron mainly ferrihydrite-iron. The R2* values showed that the red nucleus, the lateral division of the thalamus, and the substantia nigra were heavily iron-loaded, which is in agreement with a recent *in vivo* study in aceruloplasminemia (17). From the QSM maps an increase in the paramagnetic signal was only observable in a few selected areas. Although QSM has the potential to more specifically identify the underlying source of R2* increase, our reconstructions suffered from artefacts and the quality was not sufficient for quantitative analysis. These artefacts were likely caused by the large heterogeneity of iron accumulation within structures and the extremely short proton relaxation time as a result of the extremely high iron concentrations that impaired the detection of signal. QSM reconstruction in aceruloplasminemia might therefore benefit from lower magnetic field strengths, to partially mitigate these effects.

Of the three iron forms detected in the aceruloplasminemia brain, more than 91% was found to be associated with the ferritin storage protein and hemosiderin (ferrihydrite-iron). These findings agree with earlier histochemical studies of aceruloplasminemia brain tissue that showed the abundance of iron aggregates rich in Fe3+ that strongly reacted to ferritin light chain antibody (8, 9), and observations in healthy brain tissue (33). The concentrations of ferrihydrite-iron in the basal ganglia of our patient with aceruloplasminemia, could not be appropriately compared with results that had been previously obtained from the basal ganglia of healthy subjects and patients with neuroferritinopathy (29), due to substantial methodological differences between studies. The amount of ferrihydrite-iron in the temporal cortex of aceruloplasminemia, though, was six times higher than in healthy subjects and almost four times higher compared to patients with advanced Alzheimer’s disease that were measured under identical conditions (18, 34). Although these comparisons are limited to the temporal cortex, which is on average three times less rich in iron than the deep gray matter structures in aceruloplasminemia, they illustrates once more the severity of iron overload in aceruloplasminemia.

The distribution of ferrihydrite-iron throughout the brain in aceruloplasminemia did not reflect the total iron distribution in healthy brain tissue. While in normal ageing ferrihydrite-iron is most abundant in the globus pallidus and substantia nigra (11), in this aceruloplasminemia brain very high levels of ferrihydrite-iron were detected in the red nucleus, caudate nucleus and thalamus. In addition, the thalamus showed a striking lateralization, with the lateral part being far more abundant in ferrihydrite-iron than the medial part of the structure. This may be explained by specific pathways that have been recently highlighted as possibly involved in iron transport between the caudate nucleus and the pulvinar nucleus within the lateral division of the thalamus (17). The internal medullary lamina of the thalamus might additionally act as a barrier to prevent penetration of iron into the medial part of the structure (35).

Although it should be noted that the globus pallidus was not assessed by magnetometry in this study, focal demyelination and iron accumulation with a preference for the pulvinar thalamus and caudate nucleus has also been described in patients with multiple sclerosis (36, 37), in which neurodegeneration and atrophy of these structures has been associated with disease progression and cognitive disturbances (37). Although this suggests a specific role of the caudate nucleus and (pulvinar) thalamus in neuroinflammation and neurodegeneration, different patterns of iron accumulation have been observed in Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy (38), and other NBIA disorders (39), of which the clinical relevance remains to be elucidated.

The above-mentioned lateralization within the thalamus, which was observed with quantitative MRI, EPR and SQUID magnetometry, is in accordance with previous *in vivo* MRI findings in aceruloplasminemia (2, 20, 35). The relatively high R2* values obtained from the lateral division of the thalamus appeared to be driven by the large amount of ferrihydrite-iron in this region, while the medial part of the thalamus showed a lower R2* value despite being richer in maghemite-iron and EPR-detectable Fe3+ ions. Although the magnetization of maghemite is over two orders of magnitude higher compared to the one of ferrihydrite, its influence on iron-sensitive MRI remained limited due to the much lower concentration of maghemite nanocrystals compared to ferrihydrite (40). Even though these observations do not exclude that ferrihydrite-iron and maghemite-iron may contribute together to the increases in tissue magnetic susceptibility, ferrihydrite-iron likely remains the main driver of MRI susceptibility contrast in extremely iron-loaded cases.

The potential role of maghemite-iron in the pathogenesis of aceruloplasminemia should not be discarded purely based on its limited contribution to the total brain iron pool. Absolute SIRM values detected at 100 K in aceruloplasminemia were approximately two orders of magnitude higher than those reported in healthy subjects, at room temperature (41), which suggests that also maghemite-iron levels may have increased as a result of iron overload in aceruloplasminemia. In addition, the concentration of maghemite-iron detected in the temporal cortex of aceruloplasminemia was almost twice that of healthy controls and advanced cases of Alzheimer’s disease that were measured under identical conditions (18, 34). In contrast to ferrihydrite-iron, the regional distribution of maghemite-iron in the aceruloplasminemia brain was not substantially different from that of healthy controls (41), with the cerebellar and brain stem nuclei being relatively rich in this magnetic carrier, although thalamic structures were not specifically investigated by previous studies (41). The preserved distribution of maghemite-iron throughout the severely diseased aceruloplasminemia brain rather questions its biological relevance, which has already been a subject of debate in other iron-related neurodegenerative conditions (18, 27, 29, 30, 42).

The EPR-detected Fe3+ ions are complementary to the two above-mentioned iron forms, and may account for a part of the labile iron pool, which is implicated in the formation of reactive oxygen species, and for monomeric iron sites in the ferritin shell that are responsible for ferroxidase activity. Although EPR also has the potential to detect ferrihydrite-iron and maghemite-iron, the signal from these minerals is optimal at higher temperatures than used here (43), and would require at least ten times higher iron concentrations than found in this study to be detectable by EPR. Given its low abundance and relatively small magnetic moment, it is unlikely that Fe3+ ions significantly affect the MRI signal in aceruloplasminemia.

Our work has some limitations, the first being the long-term formalin fixation of the tissue. Since formalin fixation is known to reduce total tissue iron content and may have a detrimental effect on protein conformations (44-47), it is likely that the presented absolute concentrations of Fe3+ ions, ferrihydrite-iron and maghemite-iron in the aceruloplasminemia brain are underestimated compared to *in vivo*. Therefore, future studies should aim to minimize the duration of formalin fixation (34), and ideally include both aceruloplasminemia and control brain tissue to enable more in-depth analyses of the exact relationship between the different molecular forms of iron that are present in healthy and severely diseased states. On the other hand, the spatial distribution of the different iron forms, as presented in our work, is not significantly affected by prolonged formalin fixation (41). This is confirmed by the non-uniform distribution of iron within the thalamus in our study, which is in accordance with previous *in vivo* MRI findings in aceruloplasminemia (2, 20, 35). In addition, the reported ferrihydrite-iron and maghemite-iron concentrations should be considered as approximate rather than absolute values, given the assumptions that had to be made to obtain these iron concentrations from the SIRM values. However, we believe that reporting iron concentrations instead of SIRM values can help guiding the interpretation of the results in the context of biology. Finally, since our results are based on a single patient study, generalization to other cases should be done carefully. It should be noted, though, that the rarity of aceruloplasminemia makes the tissue availability a challenge, as illustrated by the fact that only six other autopsy cases that have been published over decades (3, 8, 9, 48).

In conclusion, ferrihydrite-iron probably is the major determinant of iron-sensitive MRI contrast, and is the most abundant iron form in the aceruloplasminemia brain. Among the studied regions, the lateral division of the thalamus, the red nucleus and the basal ganglia contained the highest amounts of ferrihydrite-iron. The maintenance of ferritin as the major iron storing protein in extremely iron-loaded brain tissue, as observed in our study, has major implications for the concept of iron chelation as the main treatment for aceruloplasminemia and other NBIA disorders. In particular, deferiprone is currently being exploited to treat several NBIA diseases (22, 49). Deferiprone is the only iron chelator known to date that is capable of transporting iron across cell membranes and across the blood brain barrier. As it selectively binds Fe3+ and is capable of directly removing Fe3+ ions from the core of ferritin (50), our findings pathophysiologically support the clinical benefit of deferiprone that has been reported in patients with aceruloplasminemia and other NBIA disorders (22, 49).

## Supporting information

Supplementary Materials [[supplements/206102_file02.pdf]](pending:yes)

## Data Availability

Data available upon request of the corresponding author

## Author contributions

**Lena H**.**P. Vroegindeweij:** Conceptualization, Methodology, Resources, Writing – Original Draft, Visualization, Project Administration; **Lucia Bossoni:** Methodology, Software, Investigation, Writing – Original Draft, Visualization, Project Administration; **Agnita J**.**W. Boon:** Conceptualization, Writing – Review & Editing; **J**.**H. Paul Wilson:** Conceptualization, Writing – Review & Editing; **Marjolein Bulk:** Resources, Writing – Review & Editing; **Martina Huber:** Resources, Writing – Review & Editing; **Jacqueline Labra-Muñoz:** Resources, Investigation, Writing – Review & Editing; **Andrew Webb:** Resources, Writing – Review & Editing; **Louise van der Weerd:** Methodology, Writing – Review & Editing, Supervision; **Janneke G. Langendonk:** Conceptualization, Methodology, Writing – Review & Editing, Supervision.

## Funding

This study was supported by the Dutch Foundation for Fundamental Research on Matter (FOM), by the Netherlands Organization for Scientific Research (NWO) through a VENI fellowship to L.B. (0.16.Veni.188.040), and a grant from the ZonMw program Innovative Medical Devices Initiative, project Imaging Dementia: Brain Matters (104003005) to M.B. M.H. and J. L.-M. are founded by the NWO Zwartekrachtprogram, Nanofront project NF17SYN05.

## Declarations of interest

none.

## Acknowledgements

The authors are very grateful to the patient with aceruloplasminemia and his family to agree with this research, would like to thank A. Lefering for access to the SQUID and technical assistance, and S.A. Bonnet and S. Zheng for access to the ICP-MS and measuring the iron concentration of the formalin solution.

*   Received October 15, 2020.
*   Revision received October 15, 2020.
*   Accepted October 20, 2020.


*   © 2020, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at [http://creativecommons.org/licenses/by-nd/4.0/](http://creativecommons.org/licenses/by-nd/4.0/)

## References

1.  1.Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals. 2003;16(1):205–13.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1023/A:1020775101654&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12572680&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000178671000020&link_type=ISI) 

2.  2.Miyajima H. Aceruloplasminemia. Neuropathology. 2015;35(1):83–90.
    
    

3.  3.Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol. 1995;37(5):646–56.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ana.410370515&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=7755360&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1995RF06900014&link_type=ISI) 

4.  4.Miyajima H. Investigated and available therapeutic options for treating aceruloplasminemia. Expert Opinion on Orphan Drugs. 2015;3(9):1011–20.
    
    

5.  5.Dobson J. Nanoscale biogenic iron oxides and neurodegenerative disease. FEBS Lett. 2001;496(1):1–5.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0014-5793(01)02386-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11343696&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000168741300001&link_type=ISI) 

6.  6.Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997;23(1):134–47.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0891-5849(96)00629-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9165306&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1997WZ43700016&link_type=ISI) 

7.  7.Kirschvink JL, Kobayashi-Kirschvink A, Woodford BJ. Magnetite biomineralization in the human brain. Proc Natl Acad Sci U S A. 1992;89(16):7683–7.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMDoiODkvMTYvNzY4MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzEwLzIwLzIwMjAuMTAuMTUuMjAyMDYxMDIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

8.  8.Kaneko K, Yoshida K, Arima K, Ohara S, Miyajima H, Kato T, et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol. 2002;61(12):1069–77.
    
    

9.  9.Kaneko K, Hineno A, Yoshida K, Ohara S, Morita H, Ikeda S. Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Hum Pathol. 2012;43(3):451–6.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21889188&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

10. 10.Gonzalez-Cuyar LF, Perry G, Miyajima H, Atwood CS, Riveros-Angel M, Lyons PF, et al. Redox active iron accumulation in aceruloplasminemia. Neuropathology. 2008;28(5):466–71.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18282164&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

11. 11.Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23(1):1–25.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.mri.2004.10.001&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15733784&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000227455500001&link_type=ISI) 

12. 12.Dusek P, Dezortova M, Wuerfel J. Imaging of iron. Int Rev Neurobiol. 2013;110:195–239.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/B978-0-12-410502-7.00010-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24209440&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

13. 13.Stuber C, Morawski M, Schafer A, Labadie C, Wahnert M, Leuze C, et al. Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. Neuroimage. 2014;93 Pt 1:95–106.
    
    

14. 14.Gong NJ, Dibb R, Bulk M, van der Weerd L, Liu C. Imaging beta amyloid aggregation and iron accumulation in Alzheimer’s disease using quantitative susceptibility mapping MRI. Neuroimage. 2019;191:176–85.
    
    

15. 15.Colgan TJ, Knobloch G, Reeder SB, Hernando D. Sensitivity of quantitative relaxometry and susceptibility mapping to microscopic iron distribution. Magn Reson Med. 2020;83(2):673–80.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mrm.27946&link_type=DOI) 

16. 16.Pan PL, Tang HH, Chen Q, Song W, Shang HF. Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up. Mov Disord. 2011;26(11):2142–4.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mds.23797&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21594898&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

17. 17.Zhou L, Chen Y, Li Y, Gharabaghi S, Chen Y, Sethi SK, et al. Intracranial iron distribution and quantification in aceruloplasminemia: A case study. Magn Reson Imaging. 2020;70:29–35.
    
    

18. 18.Bulk M, van der Weerd L, Breimer W, Lebedev N, Webb A, Goeman JJ, et al. Quantitative comparison of different iron forms in the temporal cortex of Alzheimer patients and control subjects. Sci Rep. 2018;8(1):6898.
    
    

19. 19.Vroegindeweij LH, van der Beek EH, Boon AJ, Hoogendoorn M, Kievit JA, Wilson JH, et al. Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series. Diabet Med. 2015;32(8):993–1000.
    
    

20. 20.Vroegindeweij LHP, Langendonk JG, Langeveld M, Hoogendoorn M, Kievit AJA, Di Raimondo D, et al. New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients. Parkinsonism Relat Disord. 2017;36:33–40.
    
    

21. 21.Kerkhof M, Honkoop P. Never forget aceruloplasminemia in case of highly suggestive Wilson’s disease score. Hepatology. 2014;59(4):1645–7.
    
    

22. 22.Vroegindeweij LHP, Boon AJW, Wilson JHP, Langendonk JG. Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports. Orphanet journal of rare diseases. 2020;15(1):105.
    
    

23. 23.Li W, Avram AV, Wu B, Xiao X, Liu C. Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. NMR Biomed. 2014;27(2):219–27.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/nbm.3056&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24357120&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

24. 24.Li W, Wu B, Liu C. iHARPERELLA: an improved method for integrated 3D phase unwrapping and background phase removal [Abstract]. In: Proceedings of the 23rd Annual Meeting & Exhibition ISMRM, 30 May-5 June 2015; Toronto, Ontario, Canada. Available from: [http://archive.ismrm.org/2015/3313.html](http://archive.ismrm.org/2015/3313.html) [accessed 7 April 2020].
    
    

25. 25.Li W, Wang N, Yu F, Han H, Cao W, Romero R, et al. A method for estimating and removing streaking artifacts in quantitative susceptibility mapping. Neuroimage. 2015;108:111–22.
    
    

26. 26.Bulk M, Kenkhuis B, van der Graaf LM, Goeman JJ, Natté R, van der Weerd L. Postmortem T 2 *-Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2018;65:1125–37.
    
    

27. 27.Kumar P, Bulk M, Webb A, van der Weerd L, Oosterkamp TH, Huber M, et al. A novel approach to quantify different iron forms in ex-vivo human brain tissue. Sci Rep. 2016;6:38916.
    
    

28. 28.Stoll S, Schweiger A. EasySpin, a comprehensive software package for spectral simulation and analysis in EPR. J Magn Reson. 2006;178(1):42–55.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jmr.2005.08.013&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16188474&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000234722700005&link_type=ISI) 

29. 29.Hautot D, Pankhurst QA, Morris CM, Curtis A, Burn J, Dobson J. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochimica et biophysica acta. 2007;1772(1):21–5.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17097860&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000243604700003&link_type=ISI) 

30. 30.Hautot D, Pankhurst QA, Khan N, Dobson J. Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer’s disease brain tissue. Proc Biol Sci. 2003;270 Suppl 1:S62–4.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1098/rsbl.2003.0012&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12952638&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000184786900019&link_type=ISI) 

31. 31.Makhlouf SA, Parker FT, Berkowitz AE. Magnetic hysteresis anomalies in ferritin. Physical Review B. 1997;55(22):R14717–R20.
    
    

32. 32.Cao D, Li H, Pan L, Li J, Wang X, Jing P, et al. High saturation magnetization of gamma-Fe2O3 nano-particles by a facile one-step synthesis approach. Sci Rep. 2016;6:32360.
    
    

33. 33.Möller HE, Bossoni L, Connor JR, Crichton RR, Does MD, Ward RJ, et al. Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. Trends in Neurosciences. 2019;42(6):384–401.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.tins.2019.03.009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31047721&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

34. 34.van der Weerd L, Lefering A, Webb A, Egli R, Bossoni L. Effects of Alzheimer’s disease and formalin fixation on the different mineralised-iron forms in the human brain. BioRxiv 129593 [Preprint]. June 2, 2020. Available from: [https://doi.org/10.1101/2020.06.02.129593](https://doi.org/10.1101/2020.06.02.129593) [accessed 9 June 2020].
    
    

35. 35.Kim HK, Ki CS, Kim YJ, Lee MS. Radiological Findings of Two Sisters with Aceruloplasminemia Presenting with Chorea. Clinical neuroradiology. 2017;27(3):385–8.
    
    

36. 36.Hagemeier J, Yeh EA, Brown MH, Bergsland N, Dwyer MG, Carl E, et al. Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Multiple Sclerosis Journal. 2013;19(5):567–76.
    
    

37. 37.Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry. 2014;85(12):1386–95.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiam5ucCI7czo1OiJyZXNpZCI7czoxMDoiODUvMTIvMTM4NiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzEwLzIwLzIwMjAuMTAuMTUuMjAyMDYxMDIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

38. 38.Han YH, Lee JH, Kang BM, Mun CW, Baik SK, Shin YI, et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. Journal of the neurological sciences. 2013;325(1-2):29–35.
    
    

39. 39.Kruer MC, Boddaert N, Schneider SA, Houlden H, Bhatia KP, Gregory A, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol. 2012;33(3):407–14.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpuciI7czo1OiJyZXNpZCI7czo4OiIzMy8zLzQwNyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzEwLzIwLzIwMjAuMTAuMTUuMjAyMDYxMDIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

40. 40.Dobson J, Bowtell R, Garcia-Prieto A, Pankhurst Q. Safety implications of high-field MRI: actuation of endogenous magnetic iron oxides in the human body. PloS one. 2009;4(5):e5431.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19412550&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

41. 41.Gilder SA, Wack M, Kaub L, Roud SC, Petersen N, Heinsen H, et al. Distribution of magnetic remanence carriers in the human brain. Sci Rep. 2018;8(1):11363.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-018-29766-z&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30054530&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

42. 42.Pankhurst Q, Hautot D, Khan N, Dobson J. Increased levels of magnetic iron compounds in Alzheimer’s disease. J Alzheimers Dis. 2008;13(1):49–52.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18334756&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000254303400005&link_type=ISI) 

43. 43.Wajnberg E, El-Jaick LJ, Linhares MP, Esquivel DM. Ferromagnetic resonance of horse spleen ferritin: core blocking and surface ordering temperatures. Journal of magnetic resonance (San Diego, Calif : 1997). 2001;153(1):69–74.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11700082&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

44. 44.Schrag M, Dickson A, Jiffry A, Kirsch D, Vinters HV, Kirsch W. The effect of formalin fixation on the levels of brain transition metals in archived samples. Biometals. 2010;23(6):1123–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10534-010-9359-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20582563&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000284063600015&link_type=ISI) 

45. 45.Gellein K, Flaten TP, Erikson KM, Aschner M, Syversen T. Leaching of trace elements from biological tissue by formalin fixation. Biol Trace Elem Res. 2008;121(3):221–5.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s12011-007-8051-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17952381&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000253128100004&link_type=ISI) 

46. 46.Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model. Free Radical Biology and Medicine. 2010;49(11):1674–84.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.freeradbiomed.2010.08.028&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20828611&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000284555000008&link_type=ISI) 

47. 47.Kalyanaraman B, Cheng G, Zielonka J, Bennett B. Low-Temperature EPR Spectroscopy as a Probe-Free Technique for Monitoring Oxidants Formed in Tumor Cells and Tissues: Implications in Drug Resistance and OXPHOS-Targeted Therapies. Cell Biochemistry and Biophysics. 2019;77(1):89–98.
    
    

48. 48.Kawanami T, Kato T, Daimon M, Tominaga M, Sasaki H, Maeda K, et al. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. J Neurol Neurosurg Psychiatry. 1996;61(5):506–9.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiam5ucCI7czo1OiJyZXNpZCI7czo4OiI2MS81LzUwNiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIwLzEwLzIwLzIwMjAuMTAuMTUuMjAyMDYxMDIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

49. 49.Klopstock T, Tricta F, Neumayr L, Karin I, Zorzi G, Fradette C, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol. 2019;18(7):631–42.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1474-4422(19)30142-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31202468&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom) 

50. 50.Bou-Abdallah F, McNally J, Liu XX, Melman A. Oxygen catalyzed mobilization of iron from ferritin by iron(III) chelate ligands. Chemical communications (Cambridge, England). 2011;47(2):731–3.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21060922&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2020%2F10%2F20%2F2020.10.15.20206102.atom)